New drug trial targets rare, debilitating nerve disorder
NCT ID NCT07392229
Summary
This study is testing whether a drug called zanubrutinib can improve nerve function in people with a rare immune disorder called anti-MAG neuropathy. About 50 adults with confirmed diagnosis and measurable nerve disability will take the drug for 12 months to see if their neurological scores improve. The goal is to control the disease and reduce its burden, though ongoing management may still be needed.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANTI-MAG IGM-ASSOCIATED DEMYELINATING POLYNEUROPATHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.